Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Slideshows|June 29, 2020
Type 2 Diabetes, on Insulin, Not at Goal: 2 Case Studies
Author(s)Sudipa Sarkar, MD
Meet 2 type 2 diabetes patients on multiple antihyperglycemics but still not meeting the ADA recommended A1c goal of 7%. What are the next best steps?
Advertisement
The 2 patients with type 2 diabetes in these short cases will be familiar to many primary care physicians - they are both on multiple antihyperglycemic medications and appear to be adherent to their regimens and yet are still above the American Diabetes Association recommended A1c goal of 7%.
Consider the options for next steps with the short history provided by Dr Sudipa Sarkar in mind. What's the next best step?
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement